Given that our data shows that high NSMCE2 and MAL2 expression are associated with breast cancer patients’ poor survival outcomes, we next investigated if high levels of these markers could also be negatively associated with response to standard cancer therapies. Here, MAL2 is linked to breast carcinoma.